BK0414 Monoclonal Antibody Concept
- 881.007
- +21.204+2.47%
The indirect controlling shareholders of Huashen Technology (000790.SZ) increased their total shares by 1%
According to the Zhitong Finance App, Huashen Technology (000790.SZ) issued an announcement. As of the disclosure date of this announcement, the implementation period of this increase plan has passed. Chengdu Yuanhong Biotechnology Co., Ltd., the indirect controlling shareholder of the company, has increased its holdings of the company's shares by 6,280,000 shares through centralized bidding transactions through the Shenzhen Stock Exchange trading system, accounting for 1% of the current total share capital of the company, and the total amount paid is about 197636 million yuan. The current plan to increase its holdings has not yet been completed, and Chengdu Yuanhong will continue to increase its holdings in accordance with the holdings increase plan.
Fosun Pharmaceutical (02196.HK) has yet to repurchase shares
Gelonghui, May 6, 丨 Fosun Pharmaceutical (02196.HK) issued an announcement. From March 26, 2024 (that is, the date the board of directors reviewed and approved the repurchase plan) to April 30, 2024, the company has not yet repurchased shares under the repurchase plan.
Yuandong Biotech (688513.SH): 0.9086% of shares have been repurchased
Gelonghui, May 6, 丨 Yuandong Biotech (688513.SH) announced that by the end of April 2024, the company had repurchased a total of 1,092 shares of the company through centralized bidding transactions, accounting for 0.9086% of the company's total share capital. The highest purchase price was 56.05 yuan/share, the lowest price was 43.5 yuan/share, and the total transaction amount was RMB 54,282,923.09 (excluding transaction fees such as stamp duty and transaction fees).
Hengrui Pharmaceutical (600276.SH): cumulative repurchase of 0.22% of shares
Gelonghui, May 6, 丨 Hengrui Pharmaceutical (600276.SH) announced that as of April 30, 2024, the company had repurchased a total of 14,351,878 shares through centralized bidding transactions, accounting for 0.22% of the company's total share capital. The highest transaction price was 47.01 yuan/share, the lowest price was 41.09 yuan/share, and the total amount paid was 634,665,849.66 yuan (excluding transaction fees).
Express News | Fosun Pharmaceuticals: The holding subsidiary was approved for clinical trials by the US FDA
Express News | Shanghai Pharmaceuticals: Levosimendan injection approved for production
Sinopharm is consistent (000028): Fee control effects are gradually showing optimism about improving profitability throughout the year
Core view On April 25, the company released the first quarter results report of 2024. In 24Q1, it achieved operating income of 19.090 billion yuan, an increase of 2.16% over the previous year, and achieved net profit of 389 million yuan to mother, an increase of 389 million yuan over the previous year
Is Zhejiang Huahai Pharmaceutical Co., Ltd.'s (SHSE:600521) Recent Stock Performance Tethered To Its Strong Fundamentals?
Zhejiang Huahai Pharmaceutical (SHSE:600521) has had a great run on the share market with its stock up by a significant 47% over the last three months. Since the market usually pay for a company's l
Express News | Morgan Stanley raised Fosun Pharmaceuticals' H-share rating to overrated.
Haizheng Pharmaceutical: “Haizheng Dingzhan” can choose to resell
Zhejiang Haizheng Pharmaceutical Co., Ltd. announced that the closing price of the company's stock for 30 consecutive trading days from March 18, 2024 to April 30, 2024 was lower than 80% of the current share conversion price of the company's “Haizheng Transfer”. According to the agreement in the “Transaction Report”, the “Haizheng Ding Transfer” resale clause came into effect.
Shanghai Pharmaceutical (601607): Steady growth in performance is optimistic about improving operations throughout the year
Core view On April 26, the company released the first quarter results report of 2024, achieving operating income of 70.153 billion yuan, an increase of 5.93% over the previous year, and a net profit of 1,542 billion yuan, an increase of 1.6 billion yuan over the previous year
East China Pharmaceutical (000963): Steady operating performance, medical and aesthetic business maintained a good growth trend
Incident description The company disclosed its 2024 quarterly report. The company achieved operating income of 10.411 billion yuan, an increase of 2.93% over the previous year; realized net profit to mother of 862 million yuan, an increase of 14.18% over the previous year; realized non-recurring deductions
Some Investors May Be Worried About Hangzhou Alltest Biotech's (SHSE:688606) Returns On Capital
To find a multi-bagger stock, what are the underlying trends we should look for in a business? Typically, we'll want to notice a trend of growing return on capital employed (ROCE) and alongside that,
Tianshili (600535): Main product growth is steady, operating quality is healthy
Core view On the evening of April 24, the company released its report for the first quarter of 2024, achieving revenue of 2,049 billion yuan, a year-on-year decline of -1.73%; the slowdown in revenue side growth was mainly due to the cold breathing category's base compared to the same period last year
Fosun Pharmaceuticals (600196): The first quarter met expectations and expected marginal improvement
The 1Q24 results are in line with our expectations. The company announced 1Q24 results: revenue of 10.157 billion yuan, -7% YoY; attributed/deducted non-net profit of RMB610/609 million, respectively, or -38%/-34% YoY. Business
Express News | Hengrui launches GLP-1R/GIPR dual agonist weight loss phase III study
Huasun Technology to Cancel 3.8 Million Repurchased Shares
Chinese drugmaker Chengdu Huasun Technology Group (SHE:000790) will cancel 3.8 million shares that the company repurchased, the company said in its filing on the Shenzhen Stock Exchange. The shares, w
Beijing Konruns PharmaceuticalLtd's (SHSE:603590) Solid Profits Have Weak Fundamentals
Despite posting some strong earnings, the market for Beijing Konruns Pharmaceutical Co.,Ltd.'s (SHSE:603590) stock hasn't moved much. Our analysis suggests that this might be because shareholders hav
North China Pharmaceutical Company.Ltd (SHSE:600812) Strong Profits May Be Masking Some Underlying Issues
North China Pharmaceutical Company.Ltd (SHSE:600812) just released a solid earnings report, and the stock displayed some strength. Despite this, our analysis suggests that there are some factors weak
Huahai Pharmaceutical's Q1 Profit Jumps 57%, Income Up 21%
Zhejiang Huahai Pharmaceutical (SHA:600521) booked a net profit attributable to shareholders of 270.8 million yuan in the first quarter of the year, jumping 56.6% from 172.9 million yuan a year earlie